Last reviewed · How we verify
Hib-MenC-TT vaccine
Hib-MenC-TT vaccine is a Conjugate vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development for Prevention of invasive disease caused by Haemophilus influenzae type b, Neisseria meningitidis serogroups C and Y, and Streptococcus pneumoniae.
Stimulates the immune system to produce antibodies against Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y and Streptococcus pneumoniae
Stimulates the immune system to produce antibodies against Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y and Streptococcus pneumoniae Used for Prevention of invasive disease caused by Haemophilus influenzae type b, Neisseria meningitidis serogroups C and Y, and Streptococcus pneumoniae.
At a glance
| Generic name | Hib-MenC-TT vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Vaccines |
| Phase | Phase 2 |
Mechanism of action
The Hib-MenC-TT vaccine is a conjugate vaccine that combines the capsular polysaccharides of Haemophilus influenzae type b, Neisseria meningitidis serogroups C and Y, and Streptococcus pneumoniae with the diphtheria toxoid protein (TT) to enhance immunogenicity.
Approved indications
- Prevention of invasive disease caused by Haemophilus influenzae type b, Neisseria meningitidis serogroups C and Y, and Streptococcus pneumoniae
Common side effects
- Pain, redness, or swelling at the injection site
- Fever
- Fatigue
Key clinical trials
- Hepatitis B Vaccination in Infants (PHASE4)
- Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m (PHASE3)
- Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination (PHASE3)
- 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age (PHASE2)
- Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines (PHASE2)
- Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old (PHASE2)
- Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants (PHASE2)
- Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hib-MenC-TT vaccine CI brief — competitive landscape report
- Hib-MenC-TT vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Hib-MenC-TT vaccine
What is Hib-MenC-TT vaccine?
How does Hib-MenC-TT vaccine work?
What is Hib-MenC-TT vaccine used for?
Who makes Hib-MenC-TT vaccine?
What drug class is Hib-MenC-TT vaccine in?
What development phase is Hib-MenC-TT vaccine in?
What are the side effects of Hib-MenC-TT vaccine?
Related
- Drug class: All Conjugate vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Vaccines
- Indication: Drugs for Prevention of invasive disease caused by Haemophilus influenzae type b, Neisseria meningitidis serogroups C and Y, and Streptococcus pneumoniae
- Compare: Hib-MenC-TT vaccine vs similar drugs
- Pricing: Hib-MenC-TT vaccine cost, discount & access